US stocks fell for a second day Tuesday as a back-up in interest rates overshadowed a solid start to earnings reporting season.
Gene therapy company Genprex surged another 125% in morning trading on Tuesday after soaring 266% on Monday. Genprex’s gene therapy trial progress are driving strong interest.
Last week, US-based Genprex has received approval from the Safety Review Committee (SRC) to proceed to the highest dose group of 0.12mg/kg in the Phase I portion of the Acclaim-3 trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) for extensive stage small cell lung cancer (ES-SCLC).
The trial is designed to evaluate the gene therapy, along with Genentech’s Tecentriq (atezolizumab) as maintenance therapy, for ES-SCLC patients.
This latest move comes after the company completed the 0.09mg/kg dose group.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。